11 results
DEF 14A
NAMS
NewAmsterdam Pharma Company N.V.
9 May 24
Definitive proxy
4:15pm
to seeking to attain diversity and balance among directors of age, race, gender, sexual orientation, geography, ethnicity, thought, viewpoints … , sexual orientation, geography, ethnicity, thought,
viewpoints, backgrounds, skills, experience, and expertise from, among other areas, the traditional
PRE 14A
NAMS
NewAmsterdam Pharma Company N.V.
29 Apr 24
Preliminary proxy
5:00pm
among directors of age, race, gender, sexual orientation, geography, ethnicity, thought, viewpoints, backgrounds, skills, experience, and expertise … of Directors will be instructed to seek to include diverse candidates in terms of age, race, gender, sexual orientation, geography, ethnicity
10-K
2023 FY
NAMS
NewAmsterdam Pharma Company N.V.
28 Feb 24
Annual report
8:00am
and ApoB and increases in CETP, HDL-C, ApoA1 and ApoE. Pharmacokinetics and pharmacodynamics generally consistent across ethnicity, age and gender.
TA-8995
424B3
NAMS
NewAmsterdam Pharma Company N.V.
15 Aug 23
Prospectus supplement
4:52pm
and apolipoprotein E (“ApoE”). Pharmacokinetics and pharmacodynamics generally consistent across ethnicity, age and gender.
TA-8995-E02: Multiple ascending dose study
POS AM
NAMS
NewAmsterdam Pharma Company N.V.
7 Aug 23
Prospectus update (post-effective amendment)
7:56am
ethnicity, age and gender.
TA-8995-E02: Multiple ascending dose study in healthy subjects
Randomized double-blind, placebo-controlled, sequential, multiple
424B3
89jm6q9mk0f2wikawa
8 Jun 23
Prospectus supplement
5:01pm
424B3
baaxb09xkcy
6 Jun 23
Prospectus supplement
4:20pm
424B3
c2euxh39e4tpuvtw2in
25 Apr 23
Prospectus supplement
8:14am
POS AM
toy89p
17 Apr 23
Prospectus update (post-effective amendment)
9:09am
F-1
i51ldb 20lt
19 Dec 22
Registration statement (foreign)
6:22pm
- Prev
- 1
- Next